Dr. Keltner brings over 30 years of experience across the life sciences sector, holding various senior positions with a particular focus on oncology and rare diseases.
He has extensive experience of public and private financings, M&A, the formation of strategic partnerships and numerous transactions in the CRO, biotech and pharma sectors. While Chairman of Raptor Pharmaceuticals Inc., a US rare disease company, he led multiple financing rounds, product launches and the eventual sale of the Company to Horizon Pharmaceuticals in 2016. He was also a member of the Board of Mannkind Corporation through its successful Nasdaq listing, and Immunovaccine Inc. through several successful fundraises.
Dr. Keltner holds the positions of Associate Professor at Case Western Reserve School of Medicine, and Director and Lecturer in Bioethics at Columbia School of Medicine, as well as authoring numerous research papers. He is currently on the Scientific Advisory Boards of several life sciences companies across the United States. He holds an MD and a PhD in Biomedical Informatics, both from Case Western Reserve University in Cleveland.
Dr. Keltner is a member of Ergomed’s Audit and Risk Committee and Nomination Committee.
